HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use SOGROYA safely and effectively. See full prescribing information for SOGROYA.

SOGROYA® (somapacitan-beco) injection, for subcutaneous use
Initial U.S. Approval: 2020

INDICATIONS AND USAGE
SOGROYA is a human growth hormone analog indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency (1).

DOSE AND ADMINISTRATION
- Administer by subcutaneous injection to the abdomen or thigh with regular rotation of injection sites to avoid lipohypertrophy/lipoatrophy (2.1).
- Administer the prescribed dose subcutaneously one time each week (2.2).
- Initiate SOGROYA with a dosage of 1.5 mg once weekly for treatment-naïve patients and patients switching from daily growth hormone (2.2).
- Increase the weekly dosage every 2 to 4 weeks by approximately 0.5 mg to 1.5 mg until the desired response has been achieved (2.2).
- Titrate the dosage based on clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations (2.2).
- The maximum recommended dosage is 8 mg once weekly.
- See the Full Prescribing Information for dosage recommendations in patients aged 65 years and older, patients with hepatic impairment, and women receiving oral estrogen (2.3).

DOSE FORMS AND STRENGTHS
Injection: 10 mg/1.5 mL (6.7 mg/mL) somapacitan-beco single-patient-use prefilled pen (3)

CONTRAINDICATIONS
- Acute critical illness (4)
- Active malignancy (4)
- Hypersensitivity to somapacitan-beco or excipients (4)
- Active proliferative or severe non-proliferative diabetic retinopathy (4)

WARNINGS AND PRECAUTIONS
- Increased Risk of Neoplasm: There are risks of malignancy progression in patients with active malignancy and of malignant changes of preexisting nevi. Monitor patients with preexisting tumors for progression or recurrence (5.2).
- Glucose Intolerance and Diabetes Mellitus: SOGROYA may decrease insulin sensitivity, particularly at higher doses. Monitor glucose levels periodically in all patients receiving SOGROYA, especially in patients with existing diabetes mellitus or at risk for its development (5.3).
- Intracranial Hypertension (IH): Has been reported usually within 8 weeks of initiation. Perform funduscopic examinations prior to initiation and periodically thereafter. If papilledema is identified prior to initiation, evaluate the etiology and treat the underlying cause before initiating. If papilledema occurs with SOGROYA, stop treatment (5.4).
- Hypersensitivity: Serious hypersensitivity reactions may occur. In the event of an allergic reaction, seek prompt medical attention (5.5).
- Fluid Retention: May occur in adults and may be dose dependent (5.6).
- Hypoadrenalism: May occur in patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism (5.7).
- Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of SOGROYA (5.8).
- Pancreatitis: Has been reported; consider pancreatitis in patients with persistent severe abdominal pain (5.9).
- Lipohypertrophy/lipoatrophy: May occur if SOGROYA administered in the same location over a long period of time. Rotate injection sites on a regular basis (5.10).

ADVERSE REACTIONS
Adverse reactions reported in ≥2% of patients treated with SOGROYA are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
- Replacement Glucocorticoid Treatment: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SOGROYA (7).
- Cytochrome P450-Metabolized Drugs: SOGROYA may alter the clearance. Monitor carefully if used with SOGROYA (7).
- Oral Estrogen: Larger doses of SOGROYA may be required (7).
- Insulin and/or Other Hypoglycemic Agents: Dose adjustment of insulin or hypoglycemic agent may be required (5.3, 7).

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 8/2020

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
  2.1 Administration and Use Instructions
  2.2 Recommended Dosage, Titration, and Monitoring
  2.3 Recommended Dosage and Titration for Specific Populations
  2.4 Missed Doses
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
  5.1 Increased Mortality in Patients with Acute Critical Illness
  5.2 Increased Risk of Neoplasms
  5.3 Glucose Intolerance and Diabetes Mellitus
  5.4 Intracranial Hypertension
  5.5 Severe Hypersensitivity
  5.6 Fluid Retention
  5.7 Hypoadrenalism
  5.8 Hypothyroidism
  5.9 Pancreatitis
  5.10 Lipohypertrophy/Lipoatrophy
  5.11 Laboratory Tests
6 ADVERSE REACTIONS
  6.1 Clinical Trials Experience
  6.2 Immuneogenicity
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.2 Lactation
  8.4 Pediatric Use
  8.5 Geriatric Use
  8.6 Hepatic Impairment
9 DRUG ABUSE AND DEPENDENCE
  9.1 Controlled Substance
  9.2 Abuse
  9.3 Dependence
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
SOGROYA is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

2 DOSAGE AND ADMINISTRATION

2.1 Administration and Use Instructions

- Therapy with SOGROYA should be supervised by a physician who is experienced in the diagnosis and management of patients with the conditions for which SOGROYA is indicated [see Indications and Usage (1)].
- Perform fundoscopic examination before initiating treatment with SOGROYA to exclude preexisting papilledema, and periodically thereafter. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating therapy with SOGROYA [see Warnings and Precautions (5.4)].
- Administer SOGROYA by subcutaneous injection to the abdomen or thigh with regular rotation of injection sites to avoid lipohypertrophy.
- Inspect visually for particulate matter and discoloration. SOGROYA should be a clear to slightly opalescent and colorless to slightly yellow solution. If the solution is cloudy or contains particulate matter do not use.
- The SOGROYA prefilled pen dials in 0.05 mg increments and delivers doses from 0.05 mg to 4 mg.
- Instructions for delivering the dosage are provided in the PATIENT INFORMATION and INSTRUCTIONS FOR USE leaflets enclosed with the SOGROYA prefilled pen.

2.2 Recommended Dosage, Titration, and Monitoring

- Administer the prescribed dose subcutaneously one time each week (weekly).
- Initiate SOGROYA with a dosage of 1.5 mg once weekly for treatment naïve patients and patients switching from daily growth hormone (somatropin).
- Increase the weekly dosage every 2 to 4 weeks by approximately 0.5 mg to 1.5 mg until the desired response is achieved.
- Titrate the dosage based on clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations. Draw IGF-1 samples 3 to 4 days after the prior dose.
- Decrease the dosage as necessary on the basis of adverse reactions and/or serum IGF-1 concentrations above the age- and sex-specific normal range.
- The maximum recommended dosage is 8 mg once weekly.

2.3 Recommended Dosage and Titration for Specific Populations

Patients Aged 65 Years and Older
Initiate SOGROYA with a dosage of 1 mg once weekly and use smaller dose increment increases when titrating the dosage [see Use in Specific Populations (8.5)]. See above for monitoring recommendations and the maximum recommended dosage of SOGROYA [see Dosage and Administration (2.2)].

Patients with Hepatic Impairment
- SOGROYA is not recommended in patients with severe hepatic impairment.
- For patients with moderate hepatic impairment, initiate SOGROYA with a dosage of 1 mg once weekly and use smaller dose increment increases when titrating the dosage. See above for monitoring recommendations [see Dosage and Administration (2.2)]. The maximum recommended dosage is 4 mg once weekly.
- No dosage adjustment is recommended for patients with mild hepatic impairment.

Women Receiving Oral Estrogen
Initiate SOGROYA with a dosage of 2 mg once weekly [see Drug Interactions (7)]. See above for titration and monitoring recommendations and the maximum recommended dosage of SOGROYA [see Dosage and Administration (2.2)].

2.4 Missed Doses

- Administer a missed dose as soon as possible and not more than 3 days after the missed dose (72 hours).
- If more than 3 days have passed since the missed dose, skip the dose and administer the next dose on the regular dosing day.

3 DOSAGE FORMS AND STRENGTHS
Injection: 10 mg/1.5 mL (6.7 mg/mL) of somapacitan-bec0 as a clear to slightly opalescent and colorless to slightly yellow solution in a single-patient-use prefilled pen

4 CONTRAINDICATIONS
SOGROYA is contraindicated in patients with:
• Acute critical illness after open-heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure because of the risk of increased mortality with use of pharmacologic doses of SOGROYA [see Warnings and Precautions (5.1)].
• Active malignancy [see Warnings and Precautions (5.2)].
• Hypersensitivity to SOGROYA or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with other growth hormone products [see Warnings and Precautions (5.5)].
• Active proliferative or severe non-proliferative diabetic retinopathy.

5 WARNINGS AND PRECAUTIONS
5.1 Increased Mortality in Patients with Acute Critical Illness
Increased mortality has been reported after treatment with pharmacologic amounts of growth hormone products in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery and multiple accidental trauma, as well as patients with acute respiratory failure [see Contraindications (4)]. Two placebo-controlled clinical trials in non-growth hormone deficient adult patients (n=522) with these conditions in intensive care units revealed a significant increase in mortality (42% vs. 19%) among somatropin-treated patients (doses 5.3-8 mg/day) compared to those receiving placebo. The safety of continuing SOGROYA treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. SOGROYA is not indicated for the treatment of non-GH deficient adults.

5.2 Increased Risk of Neoplasms
Active Malignancy
There is an increased risk of malignancy progression with growth hormone treatment in patients with active malignancy [See Contraindications (4)]. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting therapy with SOGROYA. Discontinue SOGROYA if there is evidence of recurrent activity.

New Skin Malignancy during Treatment
There is a potential risk of malignant changes of preexisting nevi. Monitor all patients receiving SOGROYA carefully for increased growth, or potential malignant changes, of preexisting nevi. Advise patients to report changes in skin pigmentation or changes in the appearance of pre-existing nevi.

5.3 Glucose Intolerance and Diabetes Mellitus
Treatment with growth hormone products may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes mellitus has been reported in patients taking growth hormone products. Patients with undiagnosed pre-diabetes and diabetes mellitus may experience worsened glycemic control and become symptomatic. Monitor glucose levels periodically in all patients receiving SOGROYA, especially in those with risk factors for diabetes mellitus, such as obesity, or a family history of diabetes mellitus. Patients with preexisting type 1 or type 2 diabetes mellitus or pre-diabetes should be monitored closely. The doses of antidiabetic agents may require adjustment when SOGROYA is initiated.

5.4 Intracranial Hypertension
Intracranial hypertension with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in patients treated with growth hormone products. Symptoms usually occurred within the first eight (8) weeks after the initiation of growth hormone therapy. In all reported cases, intracranial hypertension-associated signs and symptoms rapidly resolved after cessation of therapy or a reduction of the growth hormone dose.

Perform fundoscopic examination before initiating treatment with SOGROYA to exclude preexisting papilledema and periodically thereafter. If papilledema is identified prior to initiation, evaluate the etiology and treat the underlying cause before initiating SOGROYA. If papilledema is observed by fundoscopy during SOGROYA treatment, treatment should be stopped. If intracranial hypertension is diagnosed, treatment with SOGROYA can be restarted at a lower dose after intracranial hypertension-associated signs and symptoms have resolved.

5.5 Severe Hypersensitivity
Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of growth hormone products. Patients should be informed that such reactions are possible, and that prompt medical attention should be sought if an allergic reaction occurs [see Contraindications (4)].

5.6 Fluid Retention
Fluid retention during SOGROYA replacement therapy may occur. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent.

5.7 Hypoadrenalism
Patients receiving growth hormone therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SOGROYA treatment. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases [see Drug Interactions (7)].
5.8 Hypothyroidism
Undiagnosed/untreated hypothyroidism may prevent an optimal response to SOGROYA. In patients with GH deficiency, central (secondary) hypothyroidism may first become evident or worsen during treatment with growth hormone therapy. Therefore, patients should have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or appropriately adjusted when indicated.

5.9 Pancreatitis
Cases of pancreatitis have been reported in patients receiving growth hormone products. Pancreatitis should be considered in patients who develop persistent severe abdominal pain.

5.10 Lipohypertrophy/Lipoatrophy
When SOGROYA is administered subcutaneously at the same site over a long period of time, tissue lipohypertrophy or lipoatrophy may result. Rotate injection sites when administering SOGROYA to reduce this risk [see Dosage and Administration (2.1)].

5.11 Laboratory Tests
Serum levels of inorganic phosphorus, alkaline phosphatase, and parathyroid hormone may increase after somatropin therapy.

6 ADVERSE REACTIONS
The following important adverse drug reactions are described elsewhere in the labeling:
- Increased mortality in patients with acute critical illness [see Warnings and Precautions (5.1)]
- Neoplasms [see Warnings and Precautions (5.2)]
- Glucose intolerance and diabetes mellitus [see Warnings and Precautions (5.3)]
- Intracranial hypertension [see Warnings and Precautions (5.4)]
- Severe hypersensitivity [see Warnings and Precautions (5.5)]
- Fluid retention [see Warnings and Precautions (5.6)]
- Hypoadrenalism [see Warnings and Precautions (5.7)]
- Hypothyroidism [see Warnings and Precautions (5.8)]
- Pancreatitis [see Warnings and Precautions (5.9)]
- Lipohypertrophy/Lipoatrophy [see Warnings and Precautions (5.10)]

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

SOGROYA was studied in adult patients with GHD in a 35-week, placebo-controlled, double-blind trial with an active-control arm [see Clinical Studies (14)]. Adverse reactions occurring >2% with SOGROYA are presented in Table 1.

Table 1: Adverse Reactions occurring >2% in Adults with GHD Treated with SOGROYA and More Frequently# than in Placebo-Treated Patients for 34 Weeks

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Placebo (N=61)</th>
<th>SOGROYA (N=120)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Back pain</td>
<td>3.3</td>
<td>10</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1.6</td>
<td>6.7</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>3.3</td>
<td>5</td>
</tr>
<tr>
<td>Sleep disorder</td>
<td>1.6</td>
<td>4.2</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1.6</td>
<td>4.2</td>
</tr>
<tr>
<td>Tonsillitis</td>
<td>1.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>1.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Adrenal insufficiency</td>
<td>1.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Blood creatine phosphokinase increase</td>
<td>0</td>
<td>3.3</td>
</tr>
<tr>
<td>Weight increased</td>
<td>0</td>
<td>3.3</td>
</tr>
<tr>
<td>Anemia</td>
<td>0</td>
<td>2.5</td>
</tr>
</tbody>
</table>

# Included adverse reactions reported with at least 1% greater incidence in SOGROYA group compared to the placebo group

More SOGROYA treated patients shifted from normal baseline levels to elevated phosphate and creatine phosphokinase levels at the end of the trial compared to the placebo group (17.5% vs 4.9% and 9.2% vs. 6.6%, respectively); these laboratory changes occurred intermittently, and were non-progressive.
6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SOGROYA with the incidence of antibodies to other products may be misleading. No antisomapacitan-beco antibodies were detected in the clinical trials in patients with GHD.

7 DRUG INTERACTIONS

Table 2 includes a list of drugs with clinically important drug interactions when administered concomitantly with SOGROYA and instructions for preventing or managing them.

Table 2: Clinically Important Drug Interactions with SOGROYA

<table>
<thead>
<tr>
<th>Replacement Glucocorticoid Treatment</th>
<th>Clinical Impact:</th>
<th>Intervention:</th>
<th>Examples:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Impact:</td>
<td>Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH inhibits 11βHSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11βHSD-1 and serum cortisol. Initiation of SOGROYA may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations.</td>
<td>Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SOGROYA [see Warnings and Precautions (5.7)].</td>
<td>Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.</td>
</tr>
<tr>
<td>Intervention:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Examples:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cytochrome P450-Metabolized Drugs

<table>
<thead>
<tr>
<th>Clinical Impact:</th>
<th>Limited published data indicate that GH treatment increases cytochrome P450 (CP450)-mediated antipyrine clearance. SOGROYA may alter the clearance of compounds known to be metabolized by CP450 liver enzymes.</th>
<th>Careful monitoring is advisable when SOGROYA is administered in combination with drugs metabolized by CP450 liver enzymes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Estrogen</td>
<td>Oral estrogens may reduce the serum IGF-1 response to SOGROYA.</td>
<td>Patients receiving oral estrogen replacement may require higher SOGROYA dosages [see Dosage and Administration (2.3)].</td>
</tr>
<tr>
<td>Insulin and/or Other Hypoglycemic Agents</td>
<td>Treatment with SOGROYA may decrease insulin sensitivity, particularly at higher doses.</td>
<td>Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other hypoglycemic agents [see Warnings and Precautions (5.3)].</td>
</tr>
</tbody>
</table>

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on SOGROYA use in pregnant women; however, published studies with short-acting recombinant growth hormone (rhGH) use in pregnant women over several decades have not identified any drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, subcutaneously administered somapacitan-beco was not teratogenic in rats or rabbits during organogenesis at doses approximately 12 times the clinical exposure at the maximum recommended human dose (MRHD) of 8 mg/week. No adverse developmental outcomes were observed in in a pre- and post-natal development study with administration of somapacitan-beco to pregnant rats from organogenesis through lactation at approximately 275 times the clinical exposure at the MRHD (see Data).

The estimated background risk of birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

In an embryo-fetal development study in rats, somapacitan-beco was administered by subcutaneous injection at doses of 2, 6, and 18 mg/kg/day during the period of organogenesis from gestation day 6 to 17. Fetal viability and development were not affected at doses up to 6 mg/kg/day (31 times the MRHD, based on AUC). Transient, fetal skeletal variations (short/bent/thickened long bones) were observed at 18 mg/kg/day (261 times the MRHD, based on AUC).
In an embryo-fetal development study in rabbits, somapacitan-beco was administered by subcutaneous injection at doses of 1, 3, and 9 mg/kg every two days during the period of organogenesis from gestation day 6 to 18. Fetal viability and development were not adversely affected at somapacitan-beco dose of 1 mg/kg every two days (12 times the MRHD, based on AUC). Reduced fetal growth was observed at doses ≥3 mg/kg every two days (≥130 times the MRHD, based on C12h).

In a pre- and post-natal development study in pregnant rats, somapacitan-beco was administered by subcutaneous injection at doses of 4, 9, and 18 mg/kg twice a week from gestation day 6 through lactation day 18. No adverse developmental effects were observed in the offspring at doses up to 9 mg/kg (275 times the MRHD, based on AUC). Increased incidence of renal pelvic dilatation was observed on post-natal day 21 at 18 mg/kg (630 times the MRHD, based on AUC), but was not observed in the adult F1 generation.

8.2 Lactation

Risk Summary

There is no information on the presence of somapacitan-beco in human milk, the effects on the breastfed infant, or the effects on milk production. Somapacitan-beco-related material was secreted into milk of lactating rats. When a substance is present in animal milk, it is likely that the substance will be present in human milk. Available published data describing administration of short-acting recombinant growth hormone (rhGH) to lactating women for 7 days reported that short-acting rhGH did not increase the normal breastmilk concentration of growth hormone and no adverse effects were reported in breastfed infants. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOGROYA and any potential adverse effects on the breastfed infant from SOGROYA or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of SOGROYA have not been established in pediatric patients.

Risks in pediatric patients associated with growth hormone use include:
- Sudden death in pediatric patients with Prader-Willi Syndrome
- Increased risk of second neoplasm in pediatric cancer survivors treated with radiation to the brain and/or head
- Slipped capital femoral epiphysis
- Progression of preexisting scoliosis
- Pancreatitis

8.5 Geriatric Use

In clinical studies a total of 52 (15.6%) of the 333 SOGROYA-treated patients were 65 years or older and 3 (0.9%) were 75 years or older [see Clinical Studies (14)]. Subjects older than 65 years appeared to have higher exposure than younger subjects at the same dose level. Elderly patients may be more sensitive to the action of somapacitan-beco, and therefore may be at increased risk for adverse reactions. Initiate SOGROYA with a dose of 1 mg once weekly and use smaller increments when increasing the dose [see Dosage and Administration (2.3)].

8.6 Hepatic Impairment

No specific dose adjustment of SOGROYA is required for patients with mild hepatic impairment. Higher somapacitan-beco exposure was observed in patients with moderate hepatic impairment. In patients with moderate hepatic impairment, initiate SOGROYA with a dose of 1 mg once weekly and use smaller increments when increasing the dose. The maximum dose should not exceed 4 mg once weekly. Somapacitan-beco was not studied in patients with severe hepatic impairment. Therefore, use of SOGROYA is not recommended in patients with severe hepatic impairment [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

SOGROYA contains somapacitan-beco, which is not a controlled substance.

9.2 Abuse

Inappropriate use of SOGROYA may result in significant negative health consequences.

9.3 Dependence

SOGROYA is not associated with drug related withdrawal adverse reactions.

10 OVERDOSAGE

Acute overdosage could lead initially to hypoglycemia and subsequently to hyperglycemia. Overdose with SOGROYA is likely to cause fluid retention. Long-term overdosage could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess endogenous growth hormone.

11 DESCRIPTION

Somapacitan-beco is a human growth hormone (hGH) analog with a single substitution in the amino acid backbone (L101C) to which an albumin-binding moiety has been attached. The albumin-binding moiety (side-chain) consists of an albumin
binder and a hydrophilic spacer attached to position 101 of the protein. The protein part consists of 191 amino acids. Somapacitan-beco is produced in *Escherichia coli* by recombinant DNA technology. The molecular formula (including the albumin-binding moiety) is C\textsubscript{1038}H\textsubscript{1609}N\textsubscript{273}O\textsubscript{319}S\textsubscript{9} and the molecular weight is 23305.10 g/mol, of which the albumin-binding moiety is 1191.39 g/mol.

Structural Formula:

SOGROYA (somapacitan-beco) injection is supplied as a sterile, clear to slightly opalescent and colorless to slightly yellow solution for subcutaneous use in a single-patient-use prefilled pen with a deliverable volume of 1.5 mL.

Each mL of SOGROYA prefilled pen contains 6.7 mg of somapacitan-beco, histidine (0.68 mg), mannitol (44 mg), phenol (4 mg), poloxamer 188 (1 mg), and Water for Injection, USP. The pH is approximately 6.8. Hydrochloric acid and sodium hydroxide may be added to adjust the pH.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco.

12.2 Pharmacodynamics
IGF-I was measured to assess the pharmacodynamic (PD) properties of somapacitan-beco. Somapacitan-beco normalizes the mean IGF-I standard deviation score (SDS) level from a baseline value below -2 to a value within the reference range (-2 to +2) in treatment-naïve adult patients with GHD [see Clinical Studies (14)].

In adult patients with GHD (n=26), somapacitan-beco induces a less than dose proportional IGF-I response at steady state. Maximum IGF-I concentrations were observed within 2 to 4 days after dosing. Similar to the somapacitan-beco exposure time course, a steady state IGF-I response was reached after 1 to 2 weekly doses with limited cumulative IGF-I response.

12.3 Pharmacokinetics
The pharmacokinetics (PK) of somapacitan-beco following subcutaneous administration have been investigated at clinically relevant doses (e.g., 0.01 to 0.32 mg/kg in healthy adults, and 0.02 to 0.12 mg/kg in adults with GHD).

Overall, somapacitan-beco displays non-linear pharmacokinetics, however in the clinically relevant dose range of somapacitan-beco in adults with GHD, somapacitan-beco pharmacokinetics are approximately linear.

Absorption
In adults with GHD, a maximum concentration of somapacitan-beco is reached 4 to 24 hours post dose.

Steady state exposure is achieved following 1 to 2 weeks of once weekly administration of subcutaneous somapacitan-beco.

Distribution
Somapacitan-beco is extensively bound (>99%) to plasma proteins.
Based on population PK analyses, the estimated volume of distribution (V/F) of somapacitan-beco in adult GHD patients is approximately 14.6 L.

**Elimination**
The plasma elimination half-life of somapacitan-beco is approximately 2 to 3 days.

**Metabolism:** Somapacitan-beco is metabolized via proteolytic cleavage of the linker sequence between the peptide backbone and albumin binder sidechain.

**Excretion:** The primary excretion routes of somapacitan-beco-related material are via the urine and feces. Approximately 81% of the dose is excreted in the urine and approximately 13% is excreted in the faces. No intact somapacitan-beco is excreted indicating full breakdown of somapacitan-beco prior to excretion.

**Specific Populations**

**Body weight:** The exposure of somapacitan-beco decreases with increasing body weight. However, the somapacitan-beco dose range of 0.1 to 8 mg/week provides adequate systemic exposure to reach target IGF-1 levels over the weight range of 34.5-150.5 kg evaluated in the clinical trials.

**Geriatric patients:** Adult patients greater than 65 years of age and geriatric patients have a higher exposure than younger subjects at the same somapacitan-beco dose [see Dosage and Administration (2.3) and Use in Specific Populations (8.5)].

**Female patients receiving estrogen:** Female patients and in particular female patients on oral estrogen, have lower exposure than males at the same somapacitan-beco dose [see Dosage and Administration (2.3) and Drug Interactions (7)].

**Hepatic impairment:** A somapacitan-beco dose of 0.08 mg/kg at steady state resulted in comparable somapacitan-beco exposure between patients with normal hepatic function and mild hepatic impairment (Child-Pugh A). However, higher exposure was observed in patients with moderate hepatic impairment (Child-Pugh B) (ratios to normal hepatic function were 4.69 and 3.52-fold increase for AUC0-168h and Cmax, respectively). Lower somapacitan-beco stimulated IGF-I levels were observed in patients with mild and moderate hepatic impairment (ratios to normal hepatic function were 0.85 and 0.75, respectively) [see Dosage and Administration (2.3) and Use in Specific Populations (8.6)].

**Renal impairment:** In general, somapacitan-beco exposure tended to increase with decreasing estimated glomerular filtration rate. A somapacitan-beco dose of 0.08 mg/kg at steady state resulted in higher exposures in patients with renal impairment, that was most pronounced for patients with severe renal impairment and patients requiring haemodialysis (AUC0-168h ratios to normal renal function were 1.75 and 1.63, respectively). Higher IGF-I AUC0-168h levels were also observed in patients with moderate and severe renal impairment and in patients requiring hemodialysis (ratios to normal renal function were 1.35, 1.40 and 1.24, respectively).

13 **NONCLINICAL TOXICOLOGY**

13.1 **Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long term studies in animals with somapacitan-beco to evaluate carcinogenic potential have not been conducted.

Somapacitan-beco was not mutagenic or clastogenic in a standard battery of genotoxicity tests (bacterial mutagenicity (Ames), human lymphocyte chromosome aberration, rat bone marrow micronucleus).

In rat studies evaluating male and female fertility, somapacitan-beco was administered by subcutaneous injection at doses of 1, 2, and 4 mg/kg twice weekly. Males were dosed from four weeks before pairing until termination and females were dosed beginning two weeks prior to mating through gestation day 7. No adverse effects were observed on male or female fertility in rats at doses up to 4 mg/kg (29 times the MRHD, based on AUC).

14 **CLINICAL STUDIES**

In a 35-week, double-blind, placebo-controlled study, treatment-naïve adult patients with GHD were randomized (2:1:2) and exposed to once-weekly SOGROYA 10 mg/1.5ml (n=120) or placebo (n=60) or a daily somatropin product 10 mg/1.5ml (n=119) for a 34-week treatment period.

In this study, patients were 51.7% female and had a mean age of 45.1 years. Most patients were 23 to 64 years old and most (69.7%) had adult onset GHD. The mean BMI was 27.4 kg/m². Overall, 66.7% were White, 28.7% were Asian and 2.3% were Black or African American; 4.5% identified as Hispanic or Latino ethnicity.

Treatment with SOGROYA demonstrated superiority compared to placebo in reduction in truncal fat percentage (%) as assessed by dual X-ray absorptiometry, with a change of -1.06 % for SOGROYA and +0.47% for placebo after 34 weeks (see Table 3). Patients treated with daily somatropin achieved a change in truncal fat % of -2.23% after 34 weeks.
Table 3: Truncal Fat % Results for weekly SOGROYA, weekly placebo and daily somatropin during the 34-week pivotal trial

<table>
<thead>
<tr>
<th>Change from baseline at 34 weeks</th>
<th>Weekly Placebo</th>
<th>Weekly SOGROYA</th>
<th>Daily Somatropin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects in FAS (N)</td>
<td>61</td>
<td>120</td>
<td>119</td>
</tr>
<tr>
<td>Truncal fat % (baseline)</td>
<td>36.9</td>
<td>39.11</td>
<td>38.10</td>
</tr>
<tr>
<td>Truncal fat %</td>
<td>0.47</td>
<td>-1.06</td>
<td>-2.23</td>
</tr>
<tr>
<td>Absolute Treatment Difference (%)* [95% Confidence Interval]</td>
<td>-1.53 [-2.68; -0.38]</td>
<td>0.0090</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: FAS = Full analysis set, N = Number of subjects in FAS. Changes in truncal fat % from baseline to 34 weeks were analyzed using an analysis of covariance model with treatment, GHD onset type, sex, region, diabetes mellitus status and sex by region by diabetes mellitus interaction as factors and baseline as a covariate incorporating a multiple imputation technique where missing week 34 values were imputed based on data from the placebo group.

*No formal statistical comparison between SOGROYA and daily somatropin was performed.

After 34 weeks SOGROYA normalized the mean IGF-I SDS level in treatment-naïve adult patients with GHD with a IGF-1 SDS of -0.17 in SOGROYA-treated patients compared to -2.62 in placebo-treated patients (see Table 4). The mean IGF-I SDS levels in daily somatropin-treated patients was -2.53 at baseline and -0.23 at 34 weeks.

Table 4: IGF-I SDS for SOGROYA compared to placebo during the 34-week pivotal trial

<table>
<thead>
<tr>
<th></th>
<th>SOGROYA</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects in FAS (N)</td>
<td>120</td>
<td>61</td>
</tr>
<tr>
<td>IGF-1 SDS values at baseline, mean</td>
<td>-2.54</td>
<td>-2.64</td>
</tr>
<tr>
<td>IGF-1 SDS value at week 34, mean</td>
<td>-0.17</td>
<td>-2.62</td>
</tr>
</tbody>
</table>

Abbreviations: IGF-I SDS: Insulin-like growth factor - I standard deviation score, FAS = full analysis set, N = Number of patients in FAS. Baseline and end of main period (week 34) are observed means. Changes from baseline to the 35-week’s measurements were analysed using a mixed-effect model for repeated measurements including treatment, GHD onset type, sex, region, diabetes mellitus and sex by region by diabetes mellitus interaction as factors and baseline as a covariate, all nested within week as a factor.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

SOGROYA (somapacitan-beco) injection is a clear to slightly opalescent and colorless to slightly yellow solution available as one 1.5 mL single-patient-use prefilled pen per carton (NDC 0169-2030-11).

Storage and Handling

Before and during use: Store in a refrigerator at 36°F to 46°F (2°C to 8°C) with the cap on and in the original carton to protect from light. Do not freeze. Do not use SOGROYA if it has been frozen. Discard prefilled pen if kept above 86°F (30°C). Avoid direct or excessive heat. Avoid sunlight.

Write the date of first use in the space provided on the carton.

Always remove and safely discard the needle after each injection and store the SOGROYA prefilled pen without an injection needle attached. Always use a new needle for each injection to prevent contamination.
Table 7: Storage conditions for SOGROYA

<table>
<thead>
<tr>
<th></th>
<th>Before first use (unopened)</th>
<th>After first use (opened)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refrigerated</td>
<td>36°F to 46°F (2°C to 8°C)</td>
<td></td>
</tr>
<tr>
<td>Room Temperature</td>
<td>up to 77°F (25°C)</td>
<td></td>
</tr>
<tr>
<td>SOGROYA</td>
<td>Until expiration date</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum 72 hours (3 days)*</td>
<td>Maximum 72 hours (3 days)*</td>
</tr>
<tr>
<td>Refrigerated</td>
<td>36°F to 46°F (2°C to 8°C)</td>
<td></td>
</tr>
<tr>
<td>Room Temperature</td>
<td>up to 77°F (25°C)</td>
<td></td>
</tr>
</tbody>
</table>

*The total time allowed at room temperature (up to 77°F [25°C]) is 72 hours (3 days) regardless of whether the product is in-use (opened) or after first use (unopened). Must discard if kept above 86°F (30°C).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

- **Neoplasms** – Advise patients to report marked changes in skin pigmentation or changes in the appearance of pre-existing nevi.
- **Fluid Retention** - Advise patients that fluid retention during SOGROYA replacement therapy may frequently occur. Inform patients of the clinical manifestations of fluid retention (e.g. edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paresthesia) and to report to their healthcare provider any of these signs or symptoms occur during treatment with SOGROYA.
- **Pancreatitis** - Advise patients that pancreatitis may develop and to report to their healthcare provider any new onset abdominal pain.
- **Hypoadrenalism** - Advise patients who have or who are at risk for corticotropic deficiency that hypoadrenalism may develop and to report to their healthcare provider if they experience hyperpigmentation, extreme fatigue, dizziness, weakness, or weight loss.
- **Hypothyroidism** - Advise patients/caregivers that undiagnosed/untreated hypothyroidism may prevent an optimal response to SOGROYA. Advise patients/caregivers they may require periodic thyroid function tests.
- **Intracranial Hypertension** - Advise patients to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting.
- **Hypersensitivity Reactions** – Advise patients that serious systemic hypersensitivity reactions (anaphylaxis and angioedema) are possible and that prompt medical attention should be sought if an allergic reaction occurs.
- **Glucose Intolerance/ Diabetes Mellitus** – Advise patients that new onset pre-/diabetes mellitus or exacerbation of preexisting diabetes mellitus can occur and monitoring of blood glucose during treatment with SOGROYA may be needed.
- **Lipohypertrophy/ Lipoatrophy** – Advise patients that lipohypertrophy or lipoatrophy can occur if SOGROYA is administered subcutaneously at the same site over a long period of time. Advise patients to rotate injection sites when administering SOGROYA to reduce this risk.

Novo Nordisk® is a registered trademark of Novo Nordisk A/S.
SOGROYA® is a registered trademark of Novo Nordisk Health Care AG.

© 2002-2020 Novo Nordisk Health Care AG


For information contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, New Jersey 08536
1-888-668-6444

Manufactured by:
Novo Nordisk Inc.
Plainsboro, NJ 08536
U.S. License No. 1261

Reference ID: 4663035
What is SOGROYA?

- SOGROYA is a prescription medicine that contains human growth hormone, the same growth hormone made by the human body.
- SOGROYA is given by injection under the skin (subcutaneous) and is used to treat adults who do not make enough growth hormone.

It is not known if SOGROYA is safe and effective in children.

Do not use SOGROYA if:

- you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing (respiratory) problems.
- you have cancer or other tumors.
- you are allergic to somapacitan-beco or any of the ingredients in SOGROYA. See the end of this Patient Information leaflet for a complete list of ingredients in SOGROYA.
- your healthcare provider tells you that you have certain types of eye problems caused by diabetes (diabetic retinopathy).

Before taking SOGROYA, tell your healthcare provider about all of your medical conditions, including if you:

- have had heart or stomach surgery, trauma or serious breathing (respiratory) problems.
- have had cancer or any tumor.
- have diabetes.
- have adrenal gland problems.
- are taking replacement therapy with glucocorticoids.
- have thyroid gland problems.
- have liver problems.
- are pregnant or plan to become pregnant. It is not known if SOGROYA will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if SOGROYA passes into your breast milk. You and your healthcare provider should decide if you will take SOGROYA while you breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOGROYA may affect how other medicines work, and other medicines may affect how SOGROYA works.

How should I use SOGROYA?

- Read the detailed Instructions for Use that come with SOGROYA.
- SOGROYA comes in 1 strength. Your healthcare provider will prescribe the dose that is right for you.
- Your healthcare provider will show you how to inject SOGROYA.
- Use SOGROYA exactly as your healthcare provider tells you to.
- Use SOGROYA 1 time each week.
- If you miss a dose of SOGROYA, take the missed dose as soon as possible within 3 days (72 hours) after the missed dose. If more than 3 days (72 hours) have passed, skip the missed dose and take your next dose on the regularly scheduled day.
- SOGROYA pens are for use by 1 person only.
- Do not share your SOGROYA pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them.

What are the possible side effects of SOGROYA?

SOGROYA may cause serious side effects, including:

- high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems.
- increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer. Your healthcare provider will need to monitor you for a return of cancer or a tumor. Contact the healthcare provider if you start to have changes in moles, birthmarks, or the color of your skin.
- new or worsening high blood sugar (hyperglycemia) or diabetes. Your blood sugar may need to be monitored during treatment with SOGROYA.
- increase in pressure in the skull (intracranial hypertension). If you have headaches, eye problems, nausea or vomiting, contact the healthcare provider.

- serious allergic reactions. Get medical help right away if you have the following symptoms:
  - swelling of your face, lips, mouth, or tongue
  - trouble breathing
  - wheezing
  - skin rashes, redness, or swelling
  - dizziness or fainting
  - fast heartbeat or pounding in your chest
severe itching

- your body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs and feet. Tell your healthcare provider if you have any of these signs or symptoms of fluid retention.

- decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your cortisol levels. Tell your healthcare provider if you have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss.

- decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well SOGROYA works. The healthcare provider will do blood tests to check your thyroid hormone levels.

- severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your healthcare provider if you have any new abdominal pain.

- loss of fat and tissue weakness in the area of skin you inject. Talk to your healthcare provider about rotating the areas where you inject SOGROYA.

- increase in phosphorus, alkaline phosphatase and parathyroid hormone levels in your blood. Your healthcare provider will do blood tests to check this.

The most common side effects of SOGROYA include:

- back pain
- joint pain
- indigestion
- sleep problems
- dizziness
- swelling of the tonsils (tonsillitis)
- vomiting
- high blood pressure
- increase in the level of an enzyme in your blood called creatine phosphokinase
- weight gain
- low red blood cells (anemia)

These are not all the possible side effects of SOGROYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Novo Nordisk at 1-888-668-6444.

How should I store SOGROYA?

- Before you use SOGROYA pens for the first time:
  - Store your new, unused SOGROYA pen in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).
  - Store your new, unused SOGROYA pen with the cap on and keep it in the original carton.
  - Do not freeze SOGROYA.
  - Keep SOGROYA away from direct heat and light.
  - Do not use SOGROYA that has been frozen or in temperatures warmer than 86ºF (30ºC).
  - Do not use SOGROYA after the expiration date printed on the carton and the pen.

- After you use SOGROYA pens and there is still medicine left:
  - Store remaining SOGROYA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC) and use within 6 weeks.
  - Store your in-use SOGROYA pen with the cap on and keep it in the original carton.

  If needed, unused and in-use SOGROYA pens can be stored out of the refrigerator. SOGROYA pens can be stored at room temperature no warmer than 77ºF (25ºC) for up to 3 days (72 hours) and then returned to the refrigerator.

Keep SOGROYA and all medicines out of the reach of children.

General information about the safe and effective use of SOGROYA.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SOGROYA for a condition for which it was not prescribed. Do not give SOGROYA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SOGROYA that is written for health professionals.

What are the ingredients in SOGROYA?

- Active ingredient: somapacitan-beco
- Inactive ingredients: histidine, mannitol, phenol, poloxamer 188, Water for Injection, and hydrochloric acid and sodium hydroxide (as needed)

Manufactured by: Novo Nordisk Inc. Plainsboro, NJ 08536

This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 0x/2020

Reference ID: 4663035
Instructions for Use
SOGROYA®
(suh-GROY-uh)
(somapacitan-beco) injection
10 mg/1.5 mL (6.7 mg/mL)

1 time each week

SOGROYA Pen

Pen window
Dose counter
Dose selector
Dose button
Pen scale
Dose pointer
Pen cap
Supplies you will need:
- SOGROYA prefilled Pen
- new injection needle. SOGROYA prefilled Pen is designed to be used with all Novo Nordisk disposable needles up to a length of 8 mm.
- sharps disposal container. See Step 5 for information on how to throw away (dispose of) used needles and Pens.
- alcohol pad
- gauze pad

How to use your SOGROYA Pen

5 steps you should follow for a SOGROYA injection:
Step 1: Prepare your SOGROYA Pen
Step 2: Check the SOGROYA flow with each new Pen
Step 3: Select your dose
Step 4: Inject your dose
Step 5: After your injection

For further information about your Pen see: Frequently Asked Questions and Important information

⚠️ Important information
Pay special attention to these notes as they are important for safe use of the Pen.

⚠️ Additional information
SOGROYA is a prefilled growth hormone Pen. It contains 10 mg of somapacitan-beco and delivers doses from 0.05 mg to 4.0 mg, in increments of 0.05 mg. **SOGROYA is for use under the skin only (subcutaneous) for injection 1 time each week.**

Do not share your SOGROYA Pen and needles with another person. You may give another person an infection or get an infection from them.

Do not use your Pen without proper training from your healthcare provider. Make sure that you are confident in giving an injection with the Pen before you start your treatment. If you are blind or have poor eyesight and cannot read the dose counter on the Pen, do not use this Pen without help. Get help from a person with good eyesight who is trained to use the Pen.
### Step 1. Prepare your SOGROYA Pen

- Wash your hands with soap and water.
- **Check the name, strength, and colored label** on your Pen to make sure that it contains SOGROYA in the right strength.
- Pull off the Pen cap.
- Turn the Pen upside down 1 or 2 times to check that the SOGROYA in your Pen is clear to almost clear and colorless to slightly yellow (See Figure A). **If SOGROYA looks cloudy, do not use the Pen.**

<table>
<thead>
<tr>
<th>![A]</th>
<th>![B]</th>
</tr>
</thead>
<tbody>
<tr>
<td>![A]</td>
<td>![B]</td>
</tr>
</tbody>
</table>

- When you are ready to give your injection, get a new disposable needle, and remove the paper tab.
- Push the needle straight onto the Pen. Turn the needle clockwise *until it is on tight* (See Figure B).

<table>
<thead>
<tr>
<th>![B]</th>
</tr>
</thead>
<tbody>
<tr>
<td>![B]</td>
</tr>
</tbody>
</table>

**Always use a new needle for each injection.** This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

<table>
<thead>
<tr>
<th>![C]</th>
</tr>
</thead>
<tbody>
<tr>
<td>![C]</td>
</tr>
</tbody>
</table>

- Pull off the outer needle cap and throw it away (dispose of) (See Figure C).

<table>
<thead>
<tr>
<th>![C]</th>
</tr>
</thead>
<tbody>
<tr>
<td>![C]</td>
</tr>
</tbody>
</table>

- Pull off the inner needle cap and throw it away (dispose of) (See Figure D).

<table>
<thead>
<tr>
<th>![D]</th>
</tr>
</thead>
<tbody>
<tr>
<td>![D]</td>
</tr>
</tbody>
</table>

⚠️ A drop of SOGROYA may appear at the needle tip. This is normal, but you must still check the SOGROYA flow with each new Pen (See Step 2).

<table>
<thead>
<tr>
<th>![D]</th>
</tr>
</thead>
<tbody>
<tr>
<td>![D]</td>
</tr>
</tbody>
</table>

⚠️ **Never use a bent or damaged needle.**
### Step 2. Check the SOGROYA flow with each new Pen

1. **If your Pen is already in use**, go to Step 3.
2. **Before using a new Pen**, check the SOGROYA flow to make sure the growth hormone can flow through the Pen and needle.
3. Turn the dose selector clockwise 1 marking on the dose counter to select 0.05 mg. You may hear a faint “click” when you turn the dose selector (See Figure E).
4. 1 marking on the dose counter equals **0.05 mg** (See Figure F).

- Hold the Pen with the needle pointing up. Press and hold in the dose button until the dose counter returns to “0”. **The “0” must line up with the dose pointer** (See Figure G).

- Check that a drop of SOGROYA appears at the needle tip (See Figure H).

   **If no SOGROYA appears**, repeat Step 2 up to 6 times.

   If you still do not see a drop of SOGROYA, **change the needle**:
   - Carefully remove the needle from the Pen by turning the needle counterclockwise. Place the needle in a sharps disposal container immediately (See Step 5).
   - Repeat Step 2 again.

**Do not use the Pen if a drop of SOGROYA still does not appear after changing the needle and repeating Step 2.** Call Novo Nordisk at 1-888-668-6444 for help.

### Step 3. Select your dose
To start, check that the dose pointer is set at “0”.
- Turn the dose selector clockwise to select the dose you need (See Figure I). When you have selected your dose, you can go to Step 4.

If there is not enough SOGROYA left to select a full dose, see Frequently Asked Questions.

The dose counter shows the dose in “mg” (See Figure J and Figure K). Always use the dose counter to select the exact dose. **Do not use the “click” sounds you hear when you turn the dose selector to select your dose. Only the dose pointer on the dose counter will show the exact dose selected.**

If you select the wrong dose, you can turn the dose selector clockwise or counterclockwise to the correct dose (See Figure L).

The Pen “clicks” sound and feel differently when the dose selector is turned clockwise, counterclockwise, or if you forcefully move it past the number of “mg” left in the Pen.

### Step 4. Inject your dose

- Select the injection site
- SOGROYA can be injected under the skin (subcutaneously) of your stomach area (abdomen) or upper legs (thighs) as instructed by your healthcare provider (See Figure M). **Change the injection site every week.**
- Wipe the injection site with an alcohol pad and let the area dry.
- Insert the needle into your skin as your healthcare provider has shown you (See Figure N).
- Make sure you can see the dose counter. **Do not cover it with your fingers.** This could block the injection.

- Press and hold down the dose button until the dose counter shows “0” (See Figure O). **The “0” must line up with the dose pointer.** You may then hear or feel a “click”.

- **Continue to hold the needle in your skin.**

  If “0” does not appear in the dose counter after continuously pressing the dose button, your needle may be blocked or damaged. See **Frequently Asked Questions**.

- **Keep the needle in your skin** after the dose counter has returned to “0”. **Count slowly to 6** to make sure that the full dose has been delivered (See Figure P).

- Carefully remove the needle from your skin (See Figure Q). If blood appears at the injection site, press lightly with a gauze pad. Do not rub the area.

  You may see a drop of SOGROYA at the needle tip after injecting. This is normal and does not affect your dose.

**Step 5. After your injection**

- Carefully remove the needle from the Pen by turning the needle counterclockwise (See Figure R).

- Place the needle in an FDA-cleared sharps disposal container immediately to reduce the risk of a needle stick (See Figure R).

  Always throw away (dispose of) the needle after each injection.

For further information about safe sharps disposal, see **Frequently Asked Questions**.

⚠ **Do not try to put the needle cap back on.** You may stick yourself with the needle.
- Put the Pen cap on your Pen after each use to protect SOGROYA from direct light (See Figure S). See "How should I store my SOGROYA Pen?".

Always remove the needle from your Pen immediately after each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

How should I store my SOGROYA Pen?

**Before you use SOGROYA Pen for the first time:**
- Store your new, unused SOGROYA Pen in a refrigerator between 36°F to 46°F (2°C to 8°C).
- Store your new, unused SOGROYA Pen with the cap on and in the original carton.
- Do not freeze SOGROYA.
- When stored in the refrigerator, do not store the SOGROYA Pen directly next to the cooling element.
- Keep SOGROYA away from direct heat and light.
- Do not use SOGROYA if it has been frozen or in temperatures warmer than 86°F (30°C).
- Do not use SOGROYA after the expiration date printed on the carton and the Pen.

**After you use SOGROYA Pen and there is still medicine left:**
- Store remaining SOGROYA in the refrigerator between 36°F to 46°F (2°C to 8°C) and use within 6 weeks.
- Store your in-use SOGROYA Pen with the cap on and keep it in the original carton.

**Do not store SOGROYA Pen with the needle attached.**

If needed, unused and in-use SOGROYA pens can be stored out of the refrigerator. SOGROYA pens can be stored at room temperature no warmer than 77°F (25°C) for up to 3 days (72 hours) and then returned to the refrigerator. Throw away (dispose of) SOGROYA if it has been stored above 77°F (25°C) for more than 3 days (72 hours) or in temperatures warmer than 86°F (30°C).

Always keep your SOGROYA Pen and needles out of reach of others, especially children.

**Frequently Asked Questions**

**How do I see how much SOGROYA is left in my Pen?**
The Pen scale shows you approximately how much SOGROYA is left in your Pen (See Figure T).

To see how much SOGROYA is left in your Pen, use the dose counter:

- Turn the dose selector clockwise until the dose counter stops. The dose pointer will line up with the number of “mg” left in the Pen. You can select a maximum dose of 4.0 mg. If the dose counter stops with the dose pointer lined up with “4.0”, at least 4.0 mg are left in your Pen.
- If the dose counter stops with the dose pointer lined up with “2.8”, only 2.8 mg are left in your Pen (See Figure U).

What if I need a larger dose than what is left in my Pen?

It is not possible to select a larger dose on the dose counter than the number of “mg” left in your Pen. If you need more SOGROYA than you have left in your Pen, you can use a new Pen or split your dose between your current Pen and a new Pen. Only split your dose if you have been trained or advised by your healthcare provider on how to do this. You may find it helpful to use a calculator to plan the doses as instructed by your healthcare provider.

Be very careful to calculate your split dose correctly so that you do not give the wrong dose. If you are not sure how to split your dose using 2 Pens, then select and inject the dose you need with a new Pen.

What if no SOGROYA appears when I check the flow?

A. Your needle may be blocked or damaged, if no SOGROYA appears at the needle tip. Remove the needle as described in Step 5 and repeat Step 1 and Step 2.

B. Your Pen may be defective, if SOGROYA still does not appear after changing the needle. Do not use the Pen. Contact Novo Nordisk at 1-888-668-6444.

What if “0” does not appear after completing my injection?

The needle may be blocked or damaged, and you have not received any SOGROYA, even though the dose counter has moved from the dose that you have set. Remove the needle as described in Step 5 and repeat Step 1 to Step 4.

How should I take care of my Pen?

Be careful not to drop your Pen or knock it against hard surfaces. Do not expose your Pen to dust, dirt, liquid, or direct light. See “How should I store SOGROYA?” Do not try to refill your Pen, it is prefilled.

What if I drop my Pen?
If you drop your Pen or think that something is wrong with it, attach a new disposable needle and check the SOGROYA flow before you inject (See Step 1 and Step 2). Do not try to repair your Pen or pull it apart.

**How do I clean my Pen?**

Do not wash, soak, or lubricate your Pen. If necessary, clean it with mild detergent on a moistened cloth.

**Frequently Asked Questions**

**How do I throw away (dispose of) used SOGROYA needles and Pens?**

Put your used needles and Pens in an FDA-cleared sharps disposal container right away after use. **Do not throw away (dispose of) loose needles and Pens in your household trash.** If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:

- made of a heavy-duty plastic,
- can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
- upright and stable during use,
- leak-resistant, and
- properly labeled to warn of hazardous waste inside the container.

When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should dispose of used needles and Pens. For more information about safe sharps disposal, and for specific information about safe sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.

Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

**Important information**

- Caregivers must be very careful when handling needles to reduce the risk of needle sticks and infection.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.


SOGROYA® is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk® is a registered trademark of Novo Nordisk A/S.

© 2004-20XX Novo Nordisk Health Care AG

For further information contact:
Novo Nordisk Inc.
800 Scudders Mill Road Plainsboro, NJ 08536, USA
1-888-668-6444
Sogroya.com

Manufactured by:
Novo Nordisk Inc.
Instructions for Use
SOGROYA®
(suh-GROY-uh)
(somapacitan-beco) injection
10 mg/1.5 mL (6.7 mg/mL)

1 time each week